Milestone Pharmaceuticals reports Q3 EPS (12c), consensus (17c)

“We are approaching our December 13 Prescription Drug User Fee Act date with optimism and excitement for the opportunity to bring CARDAMYST nasal spray to patients suffering from symptomatic PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals (MIST). “Our team has recently increased our pre-launch activities to better enable market readiness. We strengthened our balance sheet with a successful equity financing last quarter, and together with the $75 million royalty payment upon FDA approval, we believe we have resources in place to drive a successful commercial launch.”